Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

BACKGROUND: Many patients who recovered from COVID are still suffering from pulmonary dysfunction that can be persistent even for months after infection. Therefore, treatment to prevent irreversible impairment of lung function is needed. Treamid (bisamide derivative of dicarboxylic acid, BDDA) was s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazdyrev, Evgeny, Panova, Maria, Brachs, Maria, Smolyarchuk, Elena, Tsygankova, Daria, Gofman, Liudmila, Abdyusheva, Yana, Novikov, Fedor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632561/
https://www.ncbi.nlm.nih.gov/pubmed/36329513
http://dx.doi.org/10.1186/s12967-022-03660-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632561/
https://www.ncbi.nlm.nih.gov/pubmed/36329513
http://dx.doi.org/10.1186/s12967-022-03660-9

Ejemplares similares